182 related articles for article (PubMed ID: 25986064)
1. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.
Heublein S; Mayr D; Egger M; Karsten U; Goletz S; Angele M; Gallwas J; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2015 May; 34(1):50. PubMed ID: 25986064
[TBL] [Abstract][Full Text] [Related]
2. Expression of the Tumor-associated Mucin 1 Epitope Analyzed with the Humanized PankoMab-GEX™ Antibody in Malignant and Normal Tissues of the Head and Neck.
Wiest I; Alexiou C; Friese K; Betz P; Tübel J; Goletz S; Dian D; Jeschke U
Anticancer Res; 2016 Jun; 36(6):3179-84. PubMed ID: 27272845
[TBL] [Abstract][Full Text] [Related]
3. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8.
Dian D; Lenhard M; Mayr D; Heublein S; Karsten U; Goletz S; Kuhn C; Wiest I; Friese K; Weissenbacher T; Jeschke U
Histol Histopathol; 2013 Feb; 28(2):239-44. PubMed ID: 23275306
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.
Fiedler W; DeDosso S; Cresta S; Weidmann J; Tessari A; Salzberg M; Dietrich B; Baumeister H; Goletz S; Gianni L; Sessa C
Eur J Cancer; 2016 Aug; 63():55-63. PubMed ID: 27285281
[TBL] [Abstract][Full Text] [Related]
5. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.
Heublein S; Friese K; Kost B; Marmé F; Kuhn C; Mahner S; Dannecker C; Mayr D; Jeschke U; Vattai A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1899-1907. PubMed ID: 30062487
[TBL] [Abstract][Full Text] [Related]
6. TA-MUC1 epitope in non-small cell lung cancer.
Kuemmel A; Single K; Bittinger F; Faldum A; Schmidt LH; Sebastian M; Micke P; Taube C; Buhl R; Wiewrodt R
Lung Cancer; 2009 Jan; 63(1):98-105. PubMed ID: 18539357
[TBL] [Abstract][Full Text] [Related]
7. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies.
Dian D; Janni W; Kuhn C; Mayr D; Karsten U; Mylonas I; Friese K; Jeschke U
Onkologie; 2009 May; 32(5):238-44. PubMed ID: 19420969
[TBL] [Abstract][Full Text] [Related]
9. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas.
Fan XN; Karsten U; Goletz S; Cao Y
Pathol Res Pract; 2010 Aug; 206(8):585-9. PubMed ID: 20400237
[TBL] [Abstract][Full Text] [Related]
10. PankoMab: a potent new generation anti-tumour MUC1 antibody.
Danielczyk A; Stahn R; Faulstich D; Löffler A; Märten A; Karsten U; Goletz S
Cancer Immunol Immunother; 2006 Nov; 55(11):1337-47. PubMed ID: 16485130
[TBL] [Abstract][Full Text] [Related]
11. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
12. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
13. Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
Heublein S; Egger M; Zhu J; Berger L; Mayr D; Schindlbeck C; Kuhn C; Hofmann SS; Schuetz F; Jeschke U; Ditsch N
Breast Cancer Res Treat; 2020 Feb; 179(3):643-652. PubMed ID: 31828591
[TBL] [Abstract][Full Text] [Related]
14. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.
Heublein S; Page S; Mayr D; Schmoeckel E; Trillsch F; Marmé F; Mahner S; Jeschke U; Vattai A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642093
[TBL] [Abstract][Full Text] [Related]
15. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
16. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer.
Stergiou N; Nagel J; Pektor S; Heimes AS; Jäkel J; Brenner W; Schmidt M; Miederer M; Kunz H; Roesch F; Schmitt E
Int J Med Sci; 2019; 16(9):1188-1198. PubMed ID: 31588183
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.
Blixt O; Bueti D; Burford B; Allen D; Julien S; Hollingsworth M; Gammerman A; Fentiman I; Taylor-Papadimitriou J; Burchell JM
Breast Cancer Res; 2011 Mar; 13(2):R25. PubMed ID: 21385452
[TBL] [Abstract][Full Text] [Related]
19. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.
Croce MV; Isla-Larrain M; Tur R; Rabassa ME; Segal-Eiras A
Clin Exp Metastasis; 2004; 21(2):139-47. PubMed ID: 15168731
[TBL] [Abstract][Full Text] [Related]
20. Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity.
Mazor Y; Keydar I; Benhar I
Mol Immunol; 2005 Jan; 42(1):55-69. PubMed ID: 15488944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
